放疗合并化疗治疗食管癌伴声嘶86例疗效分析

Efficacy of radiotherapy combined with chemotherapy in treatment of esophageal carcinoma with hoarseness

目的比较超分割及在超分割基础上协同化疗治疗食管癌伴声嘶的疗效。方法将86例食管癌患者随机分为两个组超分割(HF)组先常规照射36～40Gy,4周后改为2次d,1.2Gy次,间隔≥6h,加量至60～70Gy;超分割协同化疗(HF+C)组在放疗的同期加用DDP20mg,d1～5;氟尿嘧啶500mg,d1～5,3～4周一次,共2次。结果HF、HF+C组1,3,5年生存率分别为60.5%、32.6%、18.6%和79.1%、48.8%、32.6%,两组比较差异有显著性(P<0.05)。结论超分割协同化疗组能提高食管癌伴声嘶的生存率,不增加毒副作用。

Objective To compare the efficacy of late hyperfractionated radiotherapy with that of radiotherapy combined with chemotherapy in treatment of esophageal cancer with hoarseness.Methods Eighty six patients of esophageal carcinoma with hoarseness were randomized into two groups:The late hyperfractionation radiation (HF) group received routine radiotherapy 2.00 Gy per day, 5 times a week to a total dose of 36 40 Gy, 4 weeks later, 1.2 Gy twice a day with a minimum interval of 6 hours between fractions to a total dose of 60 70 Gy .Combined treatment group received HF radiation as in HF group plus chemotherapy with PF regimen,ie.DDP 20mg iv drip on days 1 to 5, and 5 Fu 500 mg iv drip on days 1 to 5,3 4 weeks as one cycle, twice in total.Results The one , three , five year survival rates were 79.1% ,48.8%,32.6% respectively in combined group and 60.5% ,32.6%,18.6% respectively in simple radiotherapy group.The difference between these two groups was statistically significant( P <0.05).Conclusions Late hyperfractionated radiotherapy plus chemotherapy for esophageal cancer with hoarseness is clinically effective,and does not increase toxicity.